BioSpace News Archive

The CDC estimates that 33 percent of those with DVT will have a recurrence within 10 years; new research shows French maritime pine bark extract can reduce this risk

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2018 on Wednesday, November 7, 2018, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

RXi Pharmaceuticals Corporation today announced the closing of its previously announced underwritten public offering of 3,725,714 units at a public offering price of $0.70 per unit and 17,702,858 pre-funded units at a public offering price of $0.69 per pre-funded unit, raising gross proceeds of approximately $15 million.

Veteran Varian Leaders Kolleen T. Kennedy and Chris Toth Step into New Roles

Amedisys, Inc. announced today that it has extended its employment agreement with Paul Kusserow, its president and CEO, from September 27, 2018 to December 16, 2021, adding three more years.

Guardant Health, Inc. today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $19.00 per share.

DiaSorin Molecular LLC announced today that it has received CE marking for its new Simplexa™ VZV Direct assay. The new molecular diagnostic test enables the direct detection of varicella-zoster virus (VZV) DNA from cerebrospinal fluid (CSF).

Biktarvy Showed High Efficacy and a Demonstrated Tolerability Profile Through 96 Weeks

California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, today applauded Gov. Jerry Brown for signing Senate Bill 212, legislation to establish a statewide drugs and sharps take-back program. SB 212 was approved by the California Legislature earlier this year and signed Sept. 30, by Brown. The following statement can be attributed to Sara Radcliffe, President & CEO, CLSA:

The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. Each group is held to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.